Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07275489

CHOICE KERGUELEN 2 : Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

Living for long periods in extreme environments-like Antarctic research stations or space missions-can have a significant impact on human health, especially on the immune system. Scientists have observed that people in such isolated conditions often experience more infections and a reactivation of viruses that usually stay dormant in the body, such as Herpes viruses. These changes affect both parts of the immune system: the rapid-response "innate" system and the slower, more specific "adaptive" system.

These immune disruptions may be caused by multiple stressors: ongoing psychological stress, disturbed sleep and light cycles (circadian rhythm disruption), and the challenges of living in confined, isolated, and extreme environments. While space missions and Antarctic overwintering programs have provided some insight into these issues, scientists still lack a detailed understanding of how the immune system adapts-or fails to adapt-over time in such conditions.

To help fill this gap, the CHOICE Kerguelen 2 study will follow a group of healthy young adults who will spend one year (from November 2025 to November 2026) in Port-aux-Français, a remote French research station on the Kerguelen Islands in the sub-Antarctic. These volunteers are participating in a civic service program and will be living in a highly isolated environment for the duration of their mission. The CHOICE Kerguelen study is conducted in collaboration with the French Polar Institute (IPEV).

The goal of the study is to collect and store a broad range of biological samples-including blood, saliva, stool, urine, and hair-from these volunteers at four time points during the time of their confinement on the Kerguelent Islands: tevery three months during their stay. These samples will be than analyzed to characterize the immune profiles and intestinal microbiota of the subjects assess eventual viral reactivations and stress biological markers. These analyses will allow to better understand how the immune system reacts to prolonged isolation, and to identify immune profiles that may develop under prolonged stress and limited social contact.

The long-term aim of this project is not only to improve our understanding of human immunity in extreme environments, but also to inform medical research for people living with chronic illness. By studying healthy individuals placed in physically and mentally challenging environments, scientists can better understand how stress and isolation may weaken immune defenses. The findings may one day help design new approaches to support immune health in vulnerable populations.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Hôpital SAMUKER, Port-aux-français/ Archipel KERGUELEN /Terres Australes et Antarctiques Françaises

Port-aux-Français, Terres Australes Et Antarctiques Françaises, French Southern and Antarctic Lands

Location status: Recruiting

Location contact

Marine MEYERBER, MD

CONTACT

[email protected]

02 62 00 40 33 ext. +5

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy people aged > 18 years
  • Participant affiliated with or benefiting from a social security system
  • Participant has signed informed consent
  • Participant staying as an overwintering member at Kerguelen from November 2025 to November 2026
  • Participant included in the CELREMED research project of the University Hospital of Angers on helathy volunteers in the context of CHOICE Kerguelen 1 protocol

Exclusion criteria

  • age < 18 years
  • Pregnant, breastfeeding, or postpartum woman
  • immunocompromised people (primary immunodeficiency, HIV infection or immunosupressive treatment)
  • Person refusing to participate in the study
  • Person with a history of autoimmune disease - -Person deprived of liberty by judicial or administrative decision
  • Person undergoing involuntary psychiatric treatment
  • Person subject to a legal protection measure

Treatment and study plan

blood ponction

Other

blood ponction

urines collection

Other

urines collection

hair collection

Other

hair collection

Saliva Collection

Other

saliva collection

stools collection

Other

stools collection

Primary outcomes

  1. lymphocytes subsets during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering)

    lymphocytes subsets by flow cytometry

  2. lymphocytes subsets during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    lymphocytes subsets by flow cytometry

  3. lymphocytes subsets during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    lymphocytes subsets by flow cytometry

  4. lymphocytes subsets during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    lymphocytes subsets by flow cytometry

  5. RNAsep during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    RNAseq

  6. RNAsep during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    RNAseq

  7. RNAsep during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    RNAseq

  8. RNAsep during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    RNAseq

  9. plasmatic cytokines during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    plasmatic cytokines by Bioplex

  10. plasmatic cytokines during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    plasmatic cytokines by Bioplex

  11. plasmatic cytokines during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    plasmatic cytokines by Bioplex

  12. plasmatic cytokines during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    plasmatic cytokines by Bioplex

  13. fecal microbiota

    Time frame: At inclusion (3 months after the beginning of overwintering )

    fecal microbiota by bacterial sequencing

  14. fecal microbiota

    Time frame: At 3 months (6 months after the beginning of overwintering )

    fecal microbiota by bacterial sequencing

  15. fecal microbiota

    Time frame: At 6 months (9 months after the beginning of overwintering )

    fecal microbiota by bacterial sequencing

  16. fecal microbiota

    Time frame: At 9 months (12 months after the beginning of overwintering )

    fecal microbiota by bacterial sequencing

  17. hormonal stress markers during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry

  18. hormonal stress markers during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry

  19. hormonal stress markers during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry

  20. hormonal stress markers during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    hormonal stress markers assessment in blood/urinary/hair by Elisa and nephelemetry

  21. stress profile during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    psychological stress by CST test form

  22. stress profile during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    psychological stress by CST test form

  23. stress profile during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    psychological stress by CST test form

  24. stress profile during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    psychological stress by CST test form

Secondary outcomes

  1. EBV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    EBV in blood and saliva by quantitative PCR

  2. EBV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    EBV in blood and saliva by quantitative PCR

  3. EBV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    EBV in blood and saliva by quantitative PCR

  4. EBV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    EBV in blood and saliva by quantitative PCR

  5. CMV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    CMV in blood and saliva by quantitative PCR

  6. CMV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    CMV in blood and saliva by quantitative PCR

  7. CMV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    CMV in blood and saliva by quantitative PCR

  8. CMV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    CMV in blood and saliva by quantitative PCR

  9. HSV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    HSV in blood and saliva by quantitative PCR

  10. HSV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    HSV in blood and saliva by quantitative PCR

  11. HSV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    HSV in blood and saliva by quantitative PCR

  12. HSV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    HSV in blood and saliva by quantitative PCR

  13. TTV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At inclusion (3 months after the beginning of overwintering )

    TTV viral loads in blood and saliva by quantitative PCR

  14. TTV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 3 months (6 months after the beginning of overwintering )

    TTV viral loads in blood and saliva by quantitative PCR

  15. TTV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 6 months (9 months after the beginning of overwintering )

    TTV viral loads in blood and saliva by quantitative PCR

  16. TTV viral reactivations during overwintering on the Kerguelen Islands

    Time frame: At 9 months (12 months after the beginning of overwintering )

    TTV viral loads in blood and saliva by quantitative PCR

Study contacts

Contact information is provided by the study sponsor or research team.

Anthéa LOIEZ

CONTACT

[email protected]

02 41 35 36 37 ext. +33

Charline MIOT, MD

CONTACT

[email protected]

02 41 35 36 37 ext. +33

Sponsors and collaborators

Lead sponsor

University Hospital, Angers

Other Gov

Collaborators

  • Institut Polaire Français Paul Emile Victor

Registry information

Official study title

Consequences of Longterm Confinement on Immunity in the Sub-Antarctic Islands : Follow-up of Volunteers on the Kerguelen Islands

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Dec 10, 2025
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.